| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic AcidNCT00007020 | MIRM | Phase 3 | Completed | 2009-12Actual |
| Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsNCT00053482 | Emergent BioSolutions | Phase 2 | Completed | 2003-04Actual |
| Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationNCT00053495 | Emergent BioSolutions | Phase 2 | Completed | 2003-06Actual |
| A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaNCT00081809 | AGEN | Phase 2 | Completed | 2005-06Actual |
| Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)NCT00091637 | Procter and Gamble | Phase 3 | Completed | 2007-05Actual |
| Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access GraftsNCT00131872 | LeMaitre Vascular | Phase 2 | Terminated | — |
| Study of Oxycyte in Severe Closed Head InjuryNCT00174980 | TENX | Phase 2 | Terminated | 2008-03Actual |
| Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)NCT00231062 | Integra LifeSciences Corporation | Phase 3 | Completed | 2006-06Actual |
| Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaNCT00254202 | Vanda Pharmaceuticals | Phase 3 | Completed | 2006-09-26Actual |
| Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis PatientsNCT00280917 | Can-Fite BioPharma | Phase 2 | Completed | 2007-04Actual |
| Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD ParticipantsNCT00284986 | Mesoblast, Inc. | Phase 2 | Completed | 2006-04-25Actual |
| The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00385697 | MacroGenics | Phase 2, Phase 3 | Completed | 2010-06Actual |
| Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseNCT00482092 | Mesoblast, Inc. | Phase 3 | Completed | 2014-09-15Actual |
| ACP-104 in Acutely Psychotic Subjects With SchizophreniaNCT00490516 | ACAD | Phase 2 | Completed | 2008-02Actual |
| Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseNCT00543374 | Mesoblast, Inc. | Phase 3 | Completed | 2009-07Actual |
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875 | CADL | Phase 2 | Completed | 2015-12Actual |
| Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)NCT00617981 | Imunon | Phase 3 | Completed | 2013-01Actual |
| Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic CancerNCT00625586 | MacroGenics | Phase 2 | Terminated | 2009-01-21Actual |
| Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsNCT00626236 | SUPN | Phase 2 | Completed | 2009-09-23Actual |
| Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsNCT00679172 | Emergent BioSolutions | Phase 2 | Completed | 2008-12Actual |
| PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT00683722 | Mesoblast, Inc. | Phase 2 | Completed | 2009-03-09Actual |
| PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)NCT00690066 | Mesoblast, Inc. | Phase 2 | Completed | 2010-12-12Actual |
| Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeNCT00704288 | Exelixis | Phase 2 | Completed | 2012-06Actual |
| A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibNCT00750698 | Syndax Pharmaceuticals | Phase 2 | Terminated | 2010-05Actual |
| HuMax-CD4 in Non-Cutaneous T-Cell LymphomaNCT00877656 | Emergent BioSolutions | Phase 2, Phase 3 | Completed | 2006-01Actual |
| Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)NCT00877903 | Mesoblast, Inc. | Phase 2 | Completed | 2011-05-18Actual |
| CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaNCT00893516 | Emergent BioSolutions | Phase 2 | Terminated | 2008-10Actual |
| Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246NCT00907803 | SIGA Technologies | Phase 2 | Completed | 2010-01Actual |
| Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00920582 | MacroGenics | Phase 3 | Terminated | 2012-04Actual |
| Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesNCT00940225 | Exelixis | Phase 2 | Completed | 2013-05Actual |
Trial details
- Registry ID
- NCT00007020
- Phase
- Phase 3
Trial details
- Registry ID
- NCT00053482
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00053495
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00081809
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00091637
- Phase
- Phase 3
Trial details
- Registry ID
- NCT00131872
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00174980
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00231062
- Phase
- Phase 3
Trial details
- Registry ID
- NCT00254202
- Phase
- Phase 3
Trial details
- Registry ID
- NCT00280917
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00284986
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00385697
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT00482092
- Phase
- Phase 3
Trial details
- Registry ID
- NCT00490516
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00543374
- Phase
- Phase 3
Trial details
- Registry ID
- NCT00589875
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00617981
- Phase
- Phase 3
Trial details
- Registry ID
- NCT00625586
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00626236
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00679172
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00683722
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00690066
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00704288
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00750698
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00877656
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT00877903
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00893516
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00907803
- Phase
- Phase 2
Trial details
- Registry ID
- NCT00920582
- Phase
- Phase 3
Trial details
- Registry ID
- NCT00940225
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.